Carol Aghajanian, MD
Enriched profileChief, Gynecologic Medical Oncology Service; Avon Chair in Gynecologic Oncology Research · Memorial Sloan Kettering Cancer Center
Carol Aghajanian is Chief, Gynecologic Medical Oncology Service; Avon Chair in Gynecologic Oncology Research at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 849 publications with 36,523 citations (h-index 88); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Carol Aghajanian, MD, is Chief, Gynecologic Medical Oncology Service at Memorial Sloan Kettering Cancer Center. The public record shows 849 publications with 36,523 citations (h-index 88), centered on Ovarian / Gynecologic Cancer, Sarcoma. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 6 companies, 2 NIH-funded awards (2014–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Ovarian / Gynecologic Cancer
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 11 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Commented publicly on FDA's 2022 restriction of PARP inhibitor use in non-germline-BRCA-mutated recurrent ovarian cancer
stating the withdrawal was appropriate given accumulating AML/MDS risk evidence
2022provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 27 Aug 2026
6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year202516 payments$12,991openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Gilead Sciences, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
31.1%Calcium channel blocker12.5%Amlodipine Besylate100%Part D≥18 patientsAngiotensin receptor blocker (ARB)11%Losartan Potassium100%Part D≥12 patientsNervous system
30.3%Benzodiazepine7.3%Lorazepam100%Part D<11 patientsOpioid Agonist6.4%Oxycodone Hcl54%Tramadol Hcl46%Part D<11 patientsMetabolism & gastrointestinal
16.1%Serotonin-3 Receptor Antagonist7.6%Ondansetron Hcl100%Part D≥21 patientsH2 blocker2.9%Famotidine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
2 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
- Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center
Sloan-Kettering Inst Can Research
FY2026$1,055,000UG1CA233290 - Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center
Sloan-Kettering Inst Can Research
FY2025$1,185,142UG1CA233290 - Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center
Sloan-Kettering Inst Can Research
FY2024$1,249,383UG1CA233290
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.
Clinical cancer research
Clinical Trial2026 - A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.
Clinical cancer research
Clinical Trial2025 - Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets.
Clinical cancer research
Article2023
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/carol-aghajanian-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/carol-aghajanian-md-b73554138
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Carol-Aghajanian-38575851
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/sloankettering/photos/congratulations-to-carol-aghajanian-chief-of-msks-gynecologic-medical-oncology-s/10152488309753123
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - X / Twitter
x.com/MSKCancerCenter/status/1745190694401237159
- X / Twitter
x.com/OncLive/status/1879393073928839361
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
SUNY Health Science Center at Brooklyn (SUNY Downstate)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Board Certified
Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Internal Medicine residency
Mount Sinai Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Hematology/Medical Oncology fellowship
Memorial Sloan Kettering Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Editorial & leadership roles
journal and society appointments- Chair
Gynecologic Cancer Committee, NRG Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerletter.com ↗ - Co-principal investigator
MSK participation in the Gynecologic Oncology Group (GOG); Phase I Committee member; Medical Oncology Committee member
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Co-leader
Gynecologic Oncology Disease Management Team, MSK
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center